Gelonghui, March 15, 丨 Huajian Medical (01931.HK) announced that for the year ended December 31, 2023, the Group recorded revenue of RMB 3,089 billion, an increase of 12.4% over the same period in 2022. Profit attributable to owners of parent companies was RMB 238 million, an increase of 13.4% over the same period in 2022. The increase in revenue is mainly due to increased demand for IVD products from end customers, which is due to the gradual return of hospital operations to normal after COVID-19. The increase in profit during the year was mainly due to (i) increased earnings; (ii) expenses relating to payment of employee compensation and benefits in shares under the share award scheme did not occur during the reporting period; and (iii) no impairment of property, plant and equipment and intangible assets occurred during the reporting period.